A range of active compounds are protected, each related to the active ingredient in PV-10.
Provectus is currently conducting Phase II clinical trials of its proprietary drugs PV-10 as a therapy for melanoma and breast cancer.
Craig Dees, CEO of Provectus, said: “Obtaining patent protection in India for PV-10 and our additional pipeline products is a major milestone, assuring a viable route to access a market representing roughly one-fifth of the world’s population. Additionally, as the Indian pharmaceutical industry becomes a larger player in the worldwide market, this protection establishes an important right of ownership for products sold or made in India.”